Skip to main content
Everest Organics Ltd. logo

Everest Organics Ltd. — Investor Relations & Filings

Ticker · 524790 ISIN · INE334C01029 LEI · 335800AUX9LC8WWPJC17 BSE.NS Manufacturing
Open in API
Filings indexed 2 across all filing types
Latest filing 2026-05-23 Regulatory Filings
Country IN India
Listing BSE.NS 524790

About Everest Organics Ltd.

https://www.everestorganicsltd.com/

Everest Organics Ltd. is an integrated pharmaceutical manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and bulk drug intermediates. The company maintains a diverse product portfolio with a primary focus on Proton Pump Inhibitors (PPIs), including Omeprazole, Pantoprazole, and Esomeprazole, alongside anti-bacterial agents and lipid-regulating drugs. Utilizing advanced chemical synthesis and process development, the firm operates a manufacturing infrastructure that complies with international quality standards and regulatory requirements, including USFDA guidelines. The company serves a global clientele, providing essential chemical components for the pharmaceutical formulation industry. Its technical expertise encompasses the development of complex molecules and cost-effective production processes for various therapeutic segments.

Recent filings

Filing Released Lang Actions
Enclosed the Annual Secretarial Compliance Report of the Company issued by M/s. RPR & Associates, Practising Company Secretaries for the Fianancial Year ended March 31, 2026.
Regulatory Filings Classification · 90% confidence The document is an Annual Secretarial Compliance Report filed under SEBI LODR, comprising a detailed compliance certificate by Practising Company Secretaries to the stock exchange. It is not a financial performance report (e.g., 10-K, IR), not an earnings release, and not a standalone audit opinion on financial statements. Instead, it is a regulatory compliance submission, making it a general regulatory filing. Therefore, it falls under the Regulatory Filings (RNS) category.
2026-05-23 English
Everest Organics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve a) to consider and approve ....
Regulatory Filings Classification · 75% confidence The document is a notice under SEBI LODR (Regulations 29,33) informing the stock exchange of the date of the Board meeting to consider and approve audited financial results. It does not itself contain any financial data or results, nor any change in management or voting outcome. It is a general regulatory/compliance announcement without fitting a more specific category. Therefore, it falls under Regulatory Filings (RNS) as a miscellaneous regulatory announcement.
2026-05-21 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.